Literature DB >> 7622875

Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients.

P J Carson1, R L Schut, M L Simpson, J O'Brien, E N Janoff.   

Abstract

Antibodies of the IgM class and IgG2 and IgA2 subclasses are prominent in responses to pneumococcal polysaccharides (PPS) but may be decreased in human immunodeficiency virus (HIV)-infected patients, among whom invasive pneumococcal disease is common. After immunization of HIV-infected and -seronegative subjects with pneumococcal vaccine, the number of PPS-specific antibody-secreting cells (ASC) producing IgM was significantly lower among HIV-infected subjects, whereas PPS-specific IgG and IgA ASC were more comparable. The subclass distribution of PPS-specific IgG2-producing (approximately 80%) and IgA2-producing (approximately 50%) ASC and antibodies in serum were similar. However, before immunization, the proportions of PPS-specific IgG2 for both serotypes 8 and 14 in baseline sera from HIV-infected patients were significantly decreased compared with controls. Thus, the response to PPS among HIV-infected patients may be characterized by lower levels of specific IgG2 before immunization and prominent defects in IgM responses soon after stimulation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7622875     DOI: 10.1093/infdis/172.2.340

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Antibody-enhanced pneumococcal adherence requires IgA1 protease.

Authors:  Jeffrey N Weiser; Deborah Bae; Claudine Fasching; Ronald W Scamurra; Adam J Ratner; Edward N Janoff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

2.  Hormonal milieu at time of B cell activation controls duration of autoantibody response.

Authors:  Venkatesh Jeganathan; Elena Peeva; Betty Diamond
Journal:  J Autoimmun       Date:  2014-03-28       Impact factor: 7.094

3.  Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination.

Authors:  J B Rubins; M Alter; J Loch; E N Janoff
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

Review 4.  Humoral immune responses to Streptococcus pneumoniae in the setting of HIV-1 infection.

Authors:  Lumin Zhang; Zihai Li; Zhuang Wan; Andrew Kilby; J Michael Kilby; Wei Jiang
Journal:  Vaccine       Date:  2015-06-30       Impact factor: 3.641

5.  Impaired haemophilus influenzae type b transplacental antibody transmission and declining antibody avidity through the first year of life represent potential vulnerabilities for HIV-exposed but -uninfected infants.

Authors:  James T Gaensbauer; Jeremy T Rakhola; Carolyne Onyango-Makumbi; Michael Mubiru; Jamie E Westcott; Nancy F Krebs; Edwin J Asturias; Mary Glenn Fowler; Elizabeth McFarland; Edward N Janoff
Journal:  Clin Vaccine Immunol       Date:  2014-10-08

Review 6.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

7.  The association of ethnicity with antibody responses to pneumococcal vaccination among adults with HIV infection.

Authors:  Nancy F Crum-Cianflone; Mollie Roediger; Kathy Huppler Hullsiek; Anuradha Ganesan; Michael Landrum; Amy Weintrob; Brian Agan; Sheila Medina; Jeremy Rahkola; Braden Hale; Edward N Janoff
Journal:  Vaccine       Date:  2010-09-29       Impact factor: 3.641

8.  C3b/iC3b deposition on Streptococcus pneumoniae is not affected by HIV infection.

Authors:  Catherine Hyams; Jerry C H Tam; Jeremy S Brown; Stephen B Gordon
Journal:  PLoS One       Date:  2010-01-26       Impact factor: 3.240

Review 9.  Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes.

Authors:  Andrea Cerutti; Montserrat Cols; Irene Puga
Journal:  Nat Rev Immunol       Date:  2013-02       Impact factor: 53.106

10.  A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.

Authors:  R T Perry; C V Plowe; B Koumaré; F Bougoudogo; K L Kotloff; G A Losonsky; S S Wasserman; M M Levine
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.